ORIGINAL ARTICLE

Flexible fiber cholangioscope for detection of near-infrared fluorescence



Tse-Shao Chang, MS,¹ Yaxuan Zhou, PhD,^{2,3} Ruoliu Zhang, BEng,⁴ Richard S. Kwon, MD,⁵ Erik J. Wamsteker, MD,⁵ D. Kim Turgeon, MD,⁵ Eric J. Seibel, PhD,³ Thomas D. Wang, MD, PhD^{1,4,5}

INTRODUCTION

Cholangiocarcinoma is a cancer of the bile ducts and is characterized by a high mortality rate and a steadily rising incidence.¹ This disease is usually diagnosed at an advanced stage when the prognosis is poor. Biliary intraepithelial neoplasia represents a precursor condition that can result in excellent patient outcomes with surgical resection if detected early. This condition is often suspected in patients with indeterminate biliary strictures.² Because the bile ducts are small in caliber, conventional biopsy and brushings often do not produce an adequate number of cells for either cytology or histology to make a definitive diagnosis.³ Patients often either undergo major surgery only to find a benign stricture or they delay therapy for a late-stage cancer. Therefore, a new imaging technology that can access the bile ducts to identify early biliary neoplasia is desired. We aim to demonstrate proof-ofconcept for a flexible fiber cholangioscope that is sensitive to near-infrared (NIR) fluorescence to detect targeted contrast agents in the bile ducts.

DESCRIPTION OF TECHNOLOGY

We have previously demonstrated clinical use of a flexible fiber endoscope (VerAvanti, Redmond, Wash, USA) with dimensions of 2.4 mm in diameter and 9 mm in rigid length to collect NIR fluorescence images using targeted contrast

Abbreviations: NIR, near-infrared; T/B, target-to-background.

Copyright © 2023 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 2468-4481 https://doi.org/10.1016/j.vgie.2022.10.013

Department of Mechanical Engineering, University of Michigan, Ann Arbor, Michigan (1), Department of Electrical and Computer Engineering, University of Washington, Seattle, Washington (2), Human Photonics Laboratory, Department of Mechanical Engineering, University of Washington, Seattle, Washington (3), Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan (4), Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan (5). agents.^{4,5} This instrument was used in the human esophagus to identify Barrett's neoplasia. The instrument dimensions were scaled down in size to 1.2 mm in diameter and 8 mm in rigid length to image the bile ducts (Fig. 1A). Laser excitation at $\lambda_{ex} = 635$ and 779 nm was delivered via a single-mode fiber that was scanned in a spiral pattern by a piezo tube actuator resulting in an average maximum deflection angle of $\sim 70^{\circ}$ (Fig. 1B). Two multimode fibers with core diameter of 250 µm and a numerical aperture of 0.63 were attached to the periphery of the instrument to collect fluorescence and reflectance concurrently. The cholangioscope was \sim 2.3 m in total length and passed forward easily through the working channel and elevator of a standard duodenoscope (Fig. 1C). The imaging system was contained on a portable cart for use as an accessory during ERCP (Fig. 1D). Monomer peptides QRHKPRE and KSPNPRF,^{6,7} specific for EGFR and ErbB2, respectively, were arranged in a heterodimer configuration^{8,9} (Fig. 2A and B). These peptides demonstrated increased intensity to stain human specimens of biliary intraepithelial neoplasia and early cholangiocarcinoma ex vivo by comparison with normal biliary epithelium using immunohistochemistry and immunofluorescence.¹⁰ IRDye800 was used to label the targeted contrast agent. This fluorophore emits in the spectrum with low sensitivity to hemoglobin absorption and tissue scattering and has reduced tissue autofluorescence.

CLINICAL DEMONSTRATION

Patients with indeterminate biliary strictures scheduled previously for an elective outpatient ERCP were enrolled, and informed consent was obtained. The clinical study was regulated under Investigational New Drug #139,834, approved by the Michigan Medicine Institutional Review Board, and registered online at ClinicalTrials.gov (NCT04304781). After the targeted contrast agent was administered, the cholangioscope was advanced into the bile ducts under fluoroscopy guidance to image the stricture (Video 1, available online at www. giejournal.org; Fig. 3A and B). The fluorescence images were quantified by calculating the target-to-background (T/B) ratio from individual frames using a Chan-Vese–based algorithm.¹¹ A stricture from a cholangiocarcinoma validated by pathology resulted in a T/B ratio of 1.62 (Fig. 3C). By comparison, a benign biliary stricture produced a T/B ratio of 1.00 (Fig. 3D). The



Figure 1. Near-infrared cholangioscope. **A**, En face view shows the single-mode fiber that delivers laser excitation and 2 multimode fibers (MMFs) that collect light. **B**, The rigid tip has dimensions of 8 mm in length and 1.24 mm in diameter. **C**, The cholangioscope (*arrow*) was passed forward through a push catheter (10F) before insertion into the working channel of a standard duodenoscope. **D**, The prototype imaging system was contained on a portable cart placed next to the video processor for the duodenoscope to perform ERCP.



Figure 2. Targeted contrast agent. **A**, Biochemical structure is shown for a peptide heterodimer specific for EGFR (QRHKPRE) and ErbB2 (KSPNPRF) labeled with IRDye800. **B**, Absorbance and emission spectra shown maxima at 783 and 806 nm, respectively.

coregistered reflectance image was used to interpret the fluorescence image. The cholangioscope was sterilized after each use.

CONCLUSION

We have demonstrated clinical use of a flexible fiber cholangioscope that collects NIR fluorescence images in vivo from human bile ducts. This instrument can be used with a targeted contrast agent to evaluate indeterminant biliary strictures. Larger clinical studies are needed to validate the performance of this methodology.

ACKNOWLEDGMENTS

We thank C. Olivo for fabricating the fluorescence cholangioscopes; E. Brady and C. Nolan for clinical support; J. Chen, Y. Jiang, and S. Feng for technical support; and L. Young for voice recordings.

DISCLOSURE

Dr Seibel is an inventor on patents filed by the University of Washington on the fluorescence cholangioscope and is a consultant at VerAvanti, Inc. Dr Wang is an inventor on patents filed by the University of Michigan on



Figure 3. Clinical imaging. **A**, White-light image shows insertion of cholangioscope via push catheter into the duodenal papilla. **B**, Fluoroscopy shows the presence of the cholangioscope (*arrow*) in the common bile duct. Fluorescence images are shown in the bile duct lumen (I) of a (**C**) cholangiocarcinoma (CCA), and (**D**) benign biliary stricture.

the peptide beterodimer. All other authors disclosed no financial relationships. This study was supported in part by the National Institutes of Health (grants U01 CA189291 and U54 CA163059 to T.D.W. and E.J.S.; grant R01 CA200007 to E.J.S. and T.D.W.).

REFERENCES

- 1. Gad MM, Saad AM, Faisaluddin M, et al. Epidemiology of cholangiocarcinoma; United States incidence and mortality trends. Clin Res Hepatol Gastroenterol 2020;44:885-93.
- Novikov A, Kowalski TE, Loren DE. Practical management of indeterminate biliary strictures. Gastrointest Endosc Clin N Am 2019;29: 205-14.
- Ejaz A, Cloyd JM, Pawlik TM. Advances in the diagnosis and treatment of patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020;27:552-60.
- 4. Chen J, Jiang Y, Chang T-S, et al. Multiplexed endoscopic imaging of Barrett's neoplasia using targeted fluorescent heptapeptides in a phase 1 proof-of-concept study. Gut 2021;70:1010-3.

- Chen J, Jiang Y, Chang T-S, et al. Detection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide. Endoscopy. Epub March 17, 2022. https://doi.org/10.1055/a-1801-2406.
- Zhou J, Joshi BP, Duan X, et al. EGFR overexpressed in colonic neoplasia can be detected on wide-field endoscopic imaging. Clin Transl Gastroenterol 2015;6:e101.
- Joshi BP, Zhou J, Pant A, et al. Design and synthesis of near-infrared peptide for in vivo molecular imaging of HER2. Bioconjug Chem 2016;27: 481-94.
- Chen J, Zhou J, Gao Z, et al. Multiplexed targeting of Barrett's neoplasia with a heterobivalent ligand: imaging study on mouse xenograft in vivo and human specimens ex vivo. J Med Chem 2018;61:5323-31.
- Chen J, Gao Z, Li G, et al. Dual-modal in vivo fluorescence and photoacoustic imaging using heterodimeric peptide. Chem Communicat 2018;54: 13196-9.
- Sturm MB, Joshi BP, Owens SR, et al. Multiplexed imaging strategy to distinguish indeterminant biliary strictures: an ex vivo study. World J Gastroenterol Hepatol Endosc 2020;3:1-7.
- Jiang Y, Gong Y, Rubenstein JH, et al. Toward real-time quantification of fluorescence molecular probes using target/background ratio for guiding biopsy and endoscopic therapy of esophageal neoplasia. J Med Imaging (Bellingham) 2017;4:024502.